Hengrui Pharma(SH:600276) Xin Lang Cai Jing·2025-03-28 05:13Group 1 - The medical health ETF Taikang (159760) saw a rise of over 1% in early trading on March 28, 2025, with significant trading volume, led by stocks such as Sinocelltech, Yirui Technology, and others [1] - The National Index of Public Health and Medical Health reflects the market performance of listed companies in the public health and medical health industry in the A-share market, focusing on prevention, testing, and treatment sectors, which are promising for AI technology applications [1] - As of February 28, 2025, the top ten weighted stocks in the National Index accounted for 52.4% of the index, including companies like Mindray Medical, Hengrui Medicine, and WuXi AppTec [1] Group 2 - Hengrui Medicine announced an agreement with Merck Sharp & Dohme to license its oral small molecule project for lipoprotein (a), receiving an upfront payment of $200 million and potential milestone payments up to $1.77 billion [2] - The National Medical Products Administration has announced measures to enhance support for innovative medical device development, emphasizing a tailored approach for each company [2] - Guojin Securities suggests that the pharmaceutical sector is likely to see performance improvement after the first quarter reports of 2025, recommending active investment in the sector [3]